GENB — GENERATE BIOMEDICINES INC

As of Q2 2026, 25 SEC-registered investment managers reported holding GENB (GENERATE BIOMEDICINES INC) in their latest 13F filings, with a combined reported value of $324.69M across 21.40M shares. That is +57.5% by share count (+7.81M shares) versus the previous quarter, while reported value moved +126.3%. Ownership is concentrated: the five largest holders account for 75.9% of reported value and the top ten for 95.8%.

Compared with the prior quarter, 11 opened new positions, 10 added to existing stakes, 3 trimmed, 2 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.

GENB is classified in the Health Care sector.

All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.